GeoVax and City of Hope to collaborate on City of Hope’s COVID-19 vaccine for immunocompromised patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GeoVax Labs Inc. and City of Hope entered into a license agreement granting GeoVax exclusive rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 investigational vaccine developed at City of Hope for immunocompromised patients. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login